Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Neurodegeneration: early-phase trial registry

2 of 2 indexed Neurodegeneration trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Neurodegeneration: 2 US clinical trials tracked, 2 recruiting.

Neurodegeneration is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Stephanie B. Seminara, MD, running 1 of these trials.

Enrollment posture brief

Registry condition neurodegeneration

OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Neurodegeneration (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Neurodegeneration

Neurodegeneration lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurodegeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurodegeneration is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Neurodegeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

MV-WALK: Moderate Volume Walking Behavioral
1 trials
MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise Behavioral
1 trials
HV-PDAE: High Volume Partnered Dance Aerobic Exercise Behavioral
1 trials
Kisspeptin 112-121 Drug
1 trials

US sites by state

Facility locations filed on Neurodegeneration trials. A trial with sites in several states counts in each.

Massachusetts 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurodegeneration page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurodegeneration condition card totals 2 registered trials; most-linked intervention MV-WALK: Moderate Volume Walking; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.